Results
eNauka >
Results >
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
| Title: | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Authors: | Herbst, Roy S; ...; Andric, Zoran G   ; ...; (broj, koautora 20) |
Issue Date: | 2019 | Publication: | ANNALS OF ONCOLOGY | ISSN: | 0923-7534 Annals of Oncology Search Idenfier |
Type: | Conference Paper | Collation: | vol. 30 str. 62-63 | WoS-ID: | 000506799900174 | URI: | https://enauka.gov.rs/handle/123456789/811704 | Project: | F. Hoffmann-La RocheHoffmann-La Roche | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
8
WEB OF SCIENCETM
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.